Navigation Links
Tris Pharma's Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
Date:7/10/2013

MONMOUTH JUNCTION, N.J., July 10, 2013 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that its generic pharmaceuticals business has launched Dextroamphetamine Sulfate Oral Solution, the first-to-market generic equivalent of ProCentra®, which is indicated for the treatment of attention deficit disorder with hyperactivity (ADHD) and narcolepsy.   

"Dextroamphetamine Sulfate Oral Solution continues Tris' track record of bringing first-ever generics to the marketplace, as it's our fourth first-to-market generic product and the first of many to be launched through our new generic pharmaceuticals business," said Ketan Mehta, President and CEO of Tris Pharma.

"With 13 FDA-approved ANDA products and a robust pipeline of ANDA development projects, we look forward to launching many more difference-making specialty generics," said Janet Penner, President of Tris' generic pharmaceuticals business.

Manufactured at Tris' U.S. Food and Drug Administration (FDA)-inspected, state-of-the-art facility in Monmouth Junction, NJ, Dextroamphetamine Sulfate Oral Solution is now available in the U.S. through wholesalers and distributors, as well as directly to the trade. Dextroamphetamine Sulfate Oral Solution was approved by the FDA on May 29, 2013. It is distributed in accordance with FDA and U.S. Drug Enforcement Administration (DEA) regulations governing the handling of CII controlled substances.

About Tris Pharma
Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies-driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse™ technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey, U.S.A. For more information, please visit http://www.trispharma.com.

ProCentra is a registered trademark of Outlook Pharmaceuticals, Inc., which is not associated with Tris Pharma.


'/>"/>
SOURCE Tris Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ePharmaSolutions Launches an Innovative Patient Recruitment Application for Windows 8
2. Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
3. In Q1 Public Biopharmas Shift Fundraising into Overdrive
4. ePharmaSolutions Wins Major Award for Life Sciences Industry Innovation
5. PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
6. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
7. Mylan Launches Generic Version of Zyprexa® Tablets
8. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
9. Mylan Launches Generic Lipitor® in Five European Countries
10. Mylan Launches Generic Version of Plavix® Tablets
11. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
Breaking Medicine News(10 mins):